Cumberland Pharmaceuticals Inc: Form 10-Q for the period ended Mar 31, 2016
Filed with the SEC on May 13, 2016 and accepted by EDGAR at May 13, 2016, 16:52 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2016-01-01 to 2016-03-31 | $7.7m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2016-01-01 to 2016-03-31 | $1.2m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2016-01-01 to 2016-03-31 | $706.5k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2016-01-01 to 2016-03-31 | −$500.6k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2016-01-01 to 2016-03-31 | $20.4k | us-gaap:InterestExpense |
| Income tax | 3 months2016-01-01 to 2016-03-31 | −$175.3k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2016-01-01 to 2016-03-31 | −$253.1k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2016-01-01 to 2016-03-31 | −$0.02 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2016-01-01 to 2016-03-31 | −$0.02 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2016-01-01 to 2016-03-31 | 16,341,481 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2016-01-01 to 2016-03-31 | $598.5k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2016-01-01 to 2016-03-31 | $73.1k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months2016-01-01 to 2016-03-31 | $979.3k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2016-03-31 | $36.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-03-31 | $64.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-03-31 | $89.2m | us-gaap:Assets |
| Current liabilities | At period end2016-03-31 | $11.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-03-31 | $13.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2016-03-31 | $75.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-16-016341. Last ingested by Listed: Nov 11, 2026, 03:05 ET. Listed shows no prices and gives no investment advice.